Cited by 86Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchViral Infections and Immunology Research

Long-term Valacyclovir Suppressive Treatment After Herpes Simplex Virus Type 2 Meningitis: A Double-Blind, Randomized Controlled Trial

Aurelius, E., Franzen-Rohl, E., Glimaker, M., Akre, O., Grillner, L., Jorup-Ronstrom, C., Studahl, M., the HSV-2 Meningitis Study Group·2012·Clinical Infectious Diseases

Abstract

BACKGROUND: Herpes simplex virus type 2 (HSV-2) is a common cause of acute and recurrent aseptic meningitis. Our aim was to determine the impact of antiviral suppression on recurrence of meningitis and to delineate the full spectrum of neurological complications. METHODS: One hundred and one patients with acute primary or recurrent HSV-2 meningitis were assigned to placebo (n = 51) or 0.5 g of valacyclovir twice daily (n = 50) for 1 year after initial treatment with 1 g of valacyclovir 3 times daily for 1 week in a prospective, placebo-controlled, multicenter trial. The primary outcome was time until recurrence of meningitis. The patients were followed up for 2 years. RESULTS: The first year, no significant difference was found between the valacyclovir and placebo groups. The second year, without study drugs, the risk of recurrence of verified and probable HSV-2 meningitis was significantly higher among patients exposed to valacyclovir (hazard ratio, 3.29 [95% confidence interval, 10.06-10.21]). One-third of the patients experienced 1-4 meningitis episodes during the study period. A considerable morbidity rate, comprising symptoms from the central, peripheral, and autonomous nervous system, was found in both groups. CONCLUSIONS: Suppressive treatment with 0.5 g of valacyclovir twice daily was not shown to prohibit recurrent meningitis and cannot be recommended for this purpose after HSV meningitis in general. Protection against mucocutaneous lesions was observed, but the dosage was probably inappropriate for the prevention of HSV activation in the central nervous system. The higher frequency of meningitis, after cessation of active drug, could be interpreted as a rebound phenomenon.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/cis031

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Valacyclovir was tested in clinical trials for antiviral suppression of recurrence of meningitis, but treatment with valacyclovir twice daily did not prevent recurrent meningitis and was not recommended for this purpose.

    “Valacyclovir was also tested in clinical trials for its antiviral suppression ability on recurrence of meningitis. However, treatment with valacyclovir (twice daily) did not prevent recurrent meningitis and was not recommended for this purpose [105, 106].”

    From Viral meningitis: an overview (2021) · cites this paper as [105]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 35 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Aurelius, E., Franzen-Rohl, E., Glimaker, M., Akre, O., Grillner, L., Jorup-Ronstrom, C., Studahl, M., & the HSV-2 Meningitis Study Group
Affiliations
  • Karolinska University Hospital (SE)
  • Sahlgrenska University Hospital (SE)
Venue
Clinical Infectious Diseases
Published
2012-03-28
Volume
54
Issue
9
Pages
1304-1313
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2148635135
Cited by
86
References
35
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 10 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 6 · 2015: 10 · 2014: 4 · 2013: 3 · 2012: 2
FWCI
4.53
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
Keywords
herpes simplex virus type 2, valacyclovir, suppressive antiviral therapy, recurrent meningitis, aseptic meningitis, neurological complications, mucocutaneous lesions, HSV reactivation
MeSH terms
Valacyclovir, Acyclovir, Adult, Antiviral Agents, Double-Blind Method, Female, Follow-Up Studies, Herpes Simplex, Humans, Male, Meningitis, Viral, Prospective Studies, Sweden, Valine, Treatment Outcome, Herpesvirus 2, Human, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review